Přehled o publikaci
2024
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
KÝR, Michal; Peter MÚDRY; Kristýna POLÁŠKOVÁ; Lenka ZDRAŽILOVÁ DUBSKÁ; Regina DEMLOVÁ et. al.Basic information
Original name
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
Authors
KÝR, Michal; Peter MÚDRY; Kristýna POLÁŠKOVÁ; Lenka ZDRAŽILOVÁ DUBSKÁ; Regina DEMLOVÁ; Jana KUBÁTOVÁ; Eva HLAVÁČKOVÁ; Kateřina ČERNÁ PILÁTOVÁ; Pavel MAZANEK; Klára VEJMĚLKOVÁ; Vítězslav DUŠEK; Pavel TINKA; Martin BALÁŽ; Tomáš MERTA; Zuzana KUTTNEROVÁ; Terézia TUREKOVÁ; Zdeněk PAVELKA; Petra POKORNÁ; Hana PÁLOVÁ; Marie MLNAŘÍKOVÁ; Marta JEŽOVÁ; Renata KELLNEROVÁ; Šárka KOZÁKOVÁ; Ondřej SLABÝ; Dalibor VALÍK and Jaroslav ŠTĚRBA
Edition
International journal of cancer, HOBOKEN, International Union Against Cancer, 2024, 0020-7136
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Lékařská fakulta – Repository – Repository
UT WoS
001260796700001
EID Scopus
2-s2.0-85197461804
Keywords in English
cancer vaccine; immunotherapy; metronomic chemotherapy; N-of-1; rare cancer
Links
LX22NPO5102, research and development project. MUNI/A/1395/2022, interní kód Repo. MUNI/A/1625/2023, interní kód Repo. NV19-03-00562, research and development project. 101059788, interní kód Repo. CZECRIN IV, large research infrastructures.
Changed: 13/3/2025 00:50, RNDr. Daniel Jakubík
Abstract
V originále
A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents.
